Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort

详细信息    查看全文

• 作者：Damien Pouessel¹ ; ² ; ^{damien.pouessel@aphp.fr} ; Sylvie Bastuji-Garin³ ; ⁴ ; Nadine Houé ; dé ; ⁵ ; Dimitri Vordos⁶ ; Yohann Loriot⁷ ; Christine Chevreau⁸ ; Emmanuel Sevin⁹ ; Philippe Beuzeboc¹⁰ ; Alexandre de la Taille¹ ; ⁶ ; ¹¹ ; Auré ; lie Le Thuaut³ ; ⁴ ; Yves Allory¹ ; ¹¹ ; ¹² ; Sté ; phane Culine² ; ¹³
• 关键词：Bladder carcinoma ; Postoperative chemotherapy ; Prognosis ; Survivals ; Urothelial carcinoma
• 刊名：Clinical Genitourinary Cancer
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：15
• 期：1
• 页码：e45-e52
• 全文大小：396 K
• 卷排序：15

文摘

In the past decade, adjuvant chemotherapy (AC) after radical cystectomy (RC) was preferred worldwide for patients with muscle-invasive urothelial bladder cancer. In this study we aimed to determine the outcome of patients who received AC and evaluated prognostic factors associated with survival.Patients and MethodsWe retrospectively analyzed 226 consecutive patients treated in 6 academic hospitals between 2000 and 2009. Multivariate Cox proportional hazards regression adjusted for center to estimate adjusted hazard ratios (HRs) with 95% confidence intervals were used.ResultsThe median age was 62.4 (range, 35-82) years. Patients had pT3/pT4 and/or pN+ in 180 (79.6%) and 168 patients (74.3%), respectively. Median lymph node (LN) density was 25% (range, 3.1-100). Median time between RC and AC was 61.5 (range, 18-162) days. Gemcitabine with cisplatin, gemcitabine with carboplatin, and MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimens were delivered in 161 (71.2%), 49 (21.7%), and 12 patients (5.3%) of patients, respectively. The median number of cycles was 4 (range, 1-6). Thirteen patients (5.7%) with LN metastases also received adjuvant pelvic radiotherapy (ART). After a median follow-up of 4.2 years, 5-year overall survival (OS) was 40.7%. In multivariate analysis, pT ≥3 stage (HR, 1.73; P = .05), LN density >50% (HR, 1.94; P = .03), and number of AC cycles <4 (HR, 4.26; P = .001) were adverse prognostic factors for OS. ART (HR, 0.30; P = .05) tended to provide survival benefit.ConclusionClassical prognostic features associated with survival are not modified by the use of AC. Patients who derived benefit from AC had a low LN density and received at least 4 cycles of treatment.